Sinomab Bio (SINOMAB BIOSCIENCE LIMITED) filed its Monthly Return for Equity Issuer for the period ended 30 September 2026, confirming that no changes occurred in its issued share capital during the month.

• Issued Shares and Public Float As at 30 September 2026, Sinomab Bio maintained 1.39 billion ordinary shares in issue with no treasury shares on hand. The company affirmed compliance with Hong Kong’s minimum public-float requirement of 25%.

• Share Option Activity Under the 2022 Share Option Scheme (approved 26 October 2022 and amended 14 June 2024), 6.93 million options lapsed in September, trimming outstanding options to 69.49 million. No options were exercised, no new shares were issued, and no funds were raised during the month. Up to 16.93 million shares remain available for issue or transfer under existing grants, while a further 52.05 million shares could be issued upon future grants within the scheme limits.

• Other Equity Instruments There were no movements involving warrants, convertible securities, other share-issue arrangements, or treasury shares in September.

The filing, signed by Executive Director, Chairman and CEO Shui On Leung, confirms adherence to all applicable Hong Kong listing and regulatory requirements.